IPD-KIR

Conditions for acceptance of new allele sequences.

Please read the guidelines below for submitting to the IPD-KIR Database before starting the submission procedure. You must confirm you have read and agreed to these criteria during the submission process. Some criteria do not apply if you are using Next Generation Sequencing (NGS) technology.

1. Where a sequence is obtained from cDNA or where PCR products are subcloned prior to sequencing, several clones must have been sequenced.
2. Sequencing must always be performed in both directions - unless NGS is being used.
3. If direct sequencing of PCR amplified material is performed, products from at least two separate PCR reactions must have been sequenced.
4. In individuals who are heterozygous for a locus any novel alleles must be sequenced in isolation from the second allele unless NGS is being used.
5. Primer sequence used to amplify an allele must not be included in the sequence that is submitted.
6. Where possible, a novel sequence should be confirmed by typing of genomic DNA using a secondary method such as PCR-SSOP or PCR-SSP.
   1. Where a new sequence contains either a novel mutation or a previously unseen combination of nucleotides (sequence motif), this must be confirmed by a DNA typing technique. This may require the use of newly designed probes or primers to cover the new mutation; these reagents should also be described.
7. Sequences may be submitted to one of the public data repository at the following addresses:
   • EMBL: /embl/Submission/index.html
   • GenBank: http://www.ncbi.nlm.nih.gov/Genbank/submit.html
   • DDBJ: http://www.ddbj.nig.ac.jp/submission-e.html
   An accession number from one of these repositories must be obtained.
8. Where a novel sequence differs only within an intron or other non-coding region, a full length sequence must be obtained, which covers all coding and non-coding regions.
9. Novel alleles identified in patients with haematological malignancies must be confirmed in the germline. This can be done using DNA collected by a buccal swab. Sequences derived solely from tumour material will not be considered for nomenclature.
10. Presence and Absence KIR typing must be provided for all KIR loci, except the pseudogenes. In addition complete typing for the locus of the sequence being submitted must also be included.

By clicking the following button to start your submission you are confirming that you have read and understood the conditions for acceptance of allele sequences listed above.